Aurinia Pharmaceuticals Inc. (AUPH)
NASDAQ: AUPH · Real-Time Price · USD
11.55
0.00 (0.00%)
At close: Oct 17, 2025, 4:00 PM EDT
11.32
-0.23 (-1.99%)
After-hours: Oct 17, 2025, 7:40 PM EDT
Aurinia Pharmaceuticals Revenue
Aurinia Pharmaceuticals had revenue of $70.01M in the quarter ending June 30, 2025, with 22.41% growth. This brings the company's revenue in the last twelve months to $260.11M, up 25.59% year-over-year. In the year 2024, Aurinia Pharmaceuticals had annual revenue of $235.13M with 33.97% growth.
Revenue (ttm)
$260.11M
Revenue Growth
+25.59%
P/S Ratio
6.21
Revenue / Employee
$2,000,854
Employees
130
Market Cap
1.52B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 235.13M | 59.62M | 33.97% |
| Dec 31, 2023 | 175.51M | 41.48M | 30.95% |
| Dec 31, 2022 | 134.03M | 88.43M | 193.89% |
| Dec 31, 2021 | 45.61M | -4.51M | -9.00% |
| Dec 31, 2020 | 50.12M | 49.80M | 15,660.38% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
AUPH News
- 3 days ago - Aurinia Announces Upcoming Presentations of New Data on LUPKYNIS® at American College of Rheumatology Convergence and American Society of Nephrology Kidney Week 2025 - Business Wire
- 19 days ago - Aurinia Responds to Now Retracted LinkedIn Post - Business Wire
- 2 months ago - Aurinia Pharma: The Easiest Money May Have Been Made (Rating Downgrade) - Seeking Alpha
- 2 months ago - Aurinia Pharmaceuticals Inc. (AUPH) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2025 - Business Wire
- 3 months ago - Aurinia Pharmaceuticals to Release Second Quarter 2025 Financial and Operational Results on July 31, 2025 - Business Wire
- 3 months ago - The Play On Aurinia Pharmaceuticals: Rising Cash Flow Provides Opportunity - Seeking Alpha
- 3 months ago - Aurinia Announces Positive Results from Phase 1 Study of Aritinercept (AUR200) - Business Wire